Bibliographic Details
| Title: |
Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence |
| Authors: |
Ailsa J. Christiansen, João Lobo, Christian D. Fankhauser, Christian Rothermundt, Richard Cathomas, Aashil A. Batavia, Josias B. Grogg, Arnoud J. Templeton, Anita Hirschi-Blickenstorfer, Anja Lorch, Silke Gillessen, Holger Moch, Jörg Beyer, Thomas Hermanns |
| Source: |
Frontiers in Oncology, Vol 12 (2022) |
| Publisher Information: |
Frontiers Media S.A., 2022. |
| Publication Year: |
2022 |
| Collection: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: |
miRNA - microRNA, germ cell testicular cancer, serum biomarker, method optimization, clinical implementation, disease recurrence, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: |
IntroductionCurrent evidence shows that serum miR-371a-3p can identify disease recurrence in testicular germ cell tumour (TGCT) patients and correlates with tumour load. Despite convincing evidence showing the advantages of including miR-371a-3p testing to complement and overcome the classical serum tumour markers limitations, the successful introduction of a serum miRNA based test into clinical practice has been impeded by a lack of consensus regarding optimal methodologies and lack of a universal protocol and thresholds. Herein, we investigate two quantitative real-time PCR (qRT-PCR) based pipelines in detecting disease recurrence in stage I TGCT patients under active surveillance, and compare the sensitivity and specificity for each method.MethodsSequential serum samples collected from 33 stage I TGCT patients undergoing active surveillance were analysed for miR-371a-3p via qRT-PCR with and without an amplification step included.ResultsUsing a pre-amplified protocol, all known recurrences were detected via elevated miR-371a-3p expression, while without pre-amplification, we failed to detect recurrence in 3/10 known recurrence patients. For pre-amplified analysis, sensitivity and specificity was 90% and 94.4% respectively. Without amplification, sensitivity dropped to 60%, but exhibited 100% specificity.DiscussionWe conclude that incorporating pre-amplification increases sensitivity of miR-371a-3p detection, but produces more false positive results. The ideal protocol for quantification of miR-371a-3p still needs to be determined. TGCT patients undergoing active surveillance may benefit from serum miR-371a-3p quantification with earlier detection of recurrences compared to current standard methods. However, larger cross-institutional studies where samples are processed and data is analysed in a standardised manner are required prior to its routine clinical implementation. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2234-943X |
| Relation: |
https://www.frontiersin.org/articles/10.3389/fonc.2022.1056823/full; https://doaj.org/toc/2234-943X |
| DOI: |
10.3389/fonc.2022.1056823 |
| Access URL: |
https://doaj.org/article/9039fb352c16400a82b9ed88cda7aed2 |
| Accession Number: |
edsdoj.9039fb352c16400a82b9ed88cda7aed2 |
| Database: |
Directory of Open Access Journals |
